Euro Manganese stokes the coffers for trial production at Chvaletice

|

Published 01-APR-2021 08:15 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

It appears that good news comes in threes with Euro Manganese Inc. (TSX-V;ASX:EMN) updating the market on Wednesday regarding a number of developments that will provide financial strength and operational stability in the near to medium-term.

Most importantly, management informed the market of the closing of the first tranche of the AUD$30 million (approximately CAD$29 million) private placement that was initially announced on 22 March.

This consists of the sale and issuance of approximately 41.6 million CHESS Depositary Interest (CDIs) with each CDI representing one common share at a price of AU$0.60 for gross proceeds of AU$25 million, representing C$24.2 million.

The second tranche of the offering, consisting of 8,333,334 CDIs at the same issue price is expected to close in May 2021, subject to and following shareholder approval.

Net proceeds will be used to advance the company’s Chvaletice Manganese Project in the Czech Republic.

More specifically, the funds will be employed in the completion, installation and commissioning of the company’s high-purity manganese demonstration plant.

These proceeds will also cover the initial year of operating costs of the demonstration plant, the completion of the project’s permitting and feasibility study, as well as meeting certain scheduled land acquisition payments.

Initial EIT InnoEnergy Investment

In another injection of capital, EMN received an initial investment of €62,500 (circa C$93,000) from EIT InnoEnergy.

This is the first of three payments totalling €250,000 agreed to by EIT InnoEnergy [RS1] in February.

These funds will be used to support ongoing work on the project’s definitive feasibility study and the commissioning of the demonstration plant.

This should position Euro Manganese to produce large-scale samples of high-purity manganese for supply chain qualification by prospective customers, including European electric vehicle makers and battery manufacturers.

It is worth noting that EIT InnoEnergy leads the industrial stream of the European Battery Alliance, an initiative launched by The European Commission in October 2017 with the objective to build a strong and competitive battery industry in Europe.

The support of EIT is intended to help accelerate the project’s successful integration into Europe’s electric vehicle (EV) battery value chain.

Czech government extends timeline for C$27 million in tax credits

In another positive development, management advised today that the company’s eligibility timeline for approximately C$27 million in investment incentives in the form of tax credits that were granted by the Czech Republic’s Ministry of Industry and Trade had been extended to 2025.

This will be of significant benefit given operational timelines have been pushed out due to the COVID-19 pandemic.

Option Grants

In another development on the financial front, Euro Manganese has granted stock options to certain officers, employees and consultants to purchase up to an aggregate of 2,350,000 shares.

The options are exercisable for a term of ten years at an exercise price of C$0.61 per share.

The options will vest one-third on the date of grant, and one-third on each of the first and second anniversaries of the date of grant.

Exceptions to these arrangements include the options granted to officers which vest in full five years from the date of grant, and 350,000 options granted to a consultant which vest one-third on the date of grant and one-third on each of the four and eight-month anniversaries of the date of grant.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X